Metoprolol succinate er

Abstract of a scientific article on medicine and public health, the author of a scientific work is Lukina Yu. V., Deyev A. D., Dmitrieva N. A., Ivanenkova N. Yu., Serazhim A. A., Andreeva G. F., Martsevich S . YU.

Purpose of the study. To study the efficacy and safety of the new drug metoprolol tartrate of prolonged action “Egilok retard” in patients with mild and moderate arterial hypertension in comparison with the original metoprolol succinate preparation “BetalokZOK”, the possibility of achieving the target level of arterial pressure (BP) during treatment with each preparation Materials and methods. The study involved 30 people 1 1 men and 1 9 women suffering from mild and moderate arterial hypertension (AH). The study was randomized, open, crossover. Before starting the study, all previously used antihypertensive therapy was discontinued for 1 0-1 4 days. Each of the patients alternately underwent a week-long treatment with Egilocom retard (ER) and Betaloc ZOK (BZ) at a dose of 50–1,00 mg. After the cancellation of the previous antihypertensive therapy, the patient was prescribed treatment for BR or ER (according to the randomization table) in a dose of 50 mg. The drugs were taken once a day. Therapy with the first randomized drug was completed by 29 people, the second 25 patients. Two weeks later, the effectiveness of therapy was assessed by achieving the target level of blood pressure (

Related topics in medical and health research, the author of the scientific work is Lukina

Comparative study of metoprolol tartrate drug retardant egilok retarda

Aim. For metoprolol tartrate, "Egilok retard" (ER) in patients with mild to moderate arterial hypertension (AH) in comparison with the original drug of metoprolol succinat, "Betaloc zok" (BZ), possibility of blood pressure (BP) level with treatment with each drug. Material and methods. 30 patients (11 men and 1 9 women) with mild to moderate Previous antihypertensive treatment had been canceled for all the patients 10-14 days before the study started. Each patient turns out to be treated during weeks with ER and BZ 50-1 00 mg daily. After cancellation of the previous antihypertensive therapy, BZ and ER were prescribed (according to the randomization table) in 50 mg daily. Drugs were taken once per day. 29 patients completed therapy with the first drug of randomization, 25 patients with the second. After 2 weeks efficiency of treatment of BP

Metoprolol succinate er

Text of the scientific work on the topic “Comparative study of the new drug metoprolol tartrate of the prolonged action of Egilok retard and the original drug metoprolol succinate Betalok ZOK in patients with mild and moderate arterial hypertension”

COMPARATIVE STUDY OF A NEW PRODUCT

Metoprolol succinate er

METROPOLOL TARTRATE OF PROLONGED ACTION – ETHYLOK RETARD AND ORIGINAL PREPARATION METOPROLOL SUCCINATE – BETALOK ZOK IN PATIENTS WITH SOFT AND MODERN ARTERIAL HYPERTENSION

State Research Center for Preventive Medicine, Roszdrav, Moscow

Comparative study of the long-acting metoprolol tartrate drug – Egiloka retard and the original metoprolol succinate drug – Betalok ZOK in patients with mild and moderate arterial hypertension

State Research Center for Preventive Medicine, Roszdrav, Moscow.

Purpose of the study. To study the efficacy and safety of the new drug metoprolol tartrate of prolonged action “Egilok retard” in patients with mild and moderate arterial hypertension in comparison with the original metoprolol succinate drug – “Betalok ZOK”, the possibility of achieving the target level of blood pressure (BP) during treatment with each drug.

Materials and methods. The study involved 30 people – 11 men and 19 women suffering from mild and moderate arterial hypertension (AH). The study was randomized, open, crossover. Before starting the study, all patients were discontinued previously used antihypertensive therapy for 10-14 days. Each of the patients alternately underwent 6-week treatment with Egilocom retard (ER) and Betaloc ZOK (BZ) at a dose of 50-100 mg. After the cancellation of the previous antihypertensive therapy, the patient was prescribed treatment for BR or ER (according to the randomization table) in a dose of 50 mg. The drugs were taken once a day. Therapy with the first randomized drug was completed by 29 people, the second – 25 patients. Two weeks later, the effectiveness of therapy was assessed by achieving the target level of blood pressure (

Metoprolol succinate er

Media Registration Certificate El. No. FS77-52970

Like this post? Please share to your friends:
Leave a Reply